Is Rapamycin (Sirolimus) Safe in the First Trimester?

What Rapamycin Is and Why Women Take It

Sirolimus, sold under the brand name Rapamune and widely called rapamycin, is an mTOR (mechanistic target of rapamycin) inhibitor originally approved by the FDA in 1999 for kidney transplant rejection prophylaxis. It has since found off-label use in conditions including lymphangioleiomyomatosis (LAM), certain rare tumors, and, increasingly, longevity medicine, where weekly low-dose regimens (typically 1 to 6 mg once weekly) are prescribed to extend healthspan.

Women make up a significant portion of sirolimus users across all three of these categories.

Women with kidney transplants

Women of reproductive age receive kidney transplants and require lifelong immunosuppression. The pregnancy rate after kidney transplantation is estimated at roughly 1 in 50 women of childbearing age per year, making transplant-medication safety in pregnancy a genuinely pressing clinical question, not a theoretical one.

Women with LAM

Lymphangioleiomyomatosis affects almost exclusively women, typically in the reproductive years. Sirolimus is FDA-approved for LAM and has been shown in the MILES trial to stabilize lung function. Because LAM peaks in women between ages 20 and 40, the intersection with pregnancy planning is frequent.

Women using rapamycin for longevity

Off-label rapamycin prescribing for aging has increased sharply since 2020. Surveys of longevity clinics suggest that a substantial minority of users are women under 50, some of whom are in perimenopause or still in their reproductive years. No clinical trial has evaluated rapamycin for longevity in pregnant women, or in women who become pregnant while taking it. The data vacuum here is real, and you deserve to know it plainly.

How Sirolimus Works and Why That Matters for a Developing Embryo

MTOR signaling is not just a transplant or aging target. It is a master regulator of cell growth, proliferation, and differentiation throughout embryonic development. mTOR Complex 1 (mTORC1) coordinates nutrient sensing and protein synthesis in trophoblast cells, the very cells that form the placenta during the first trimester.

Blocking mTOR during the critical window of organogenesis (weeks 3 through 8 of pregnancy) carries a biologically plausible mechanism for harm: you are chemically suppressing the exact pathway that drives the early embryo's most rapid growth phase. That is not a theoretical extrapolation. The biology is consistent with the animal toxicology data, described in the next section.

Sex-specific pharmacokinetics

Women generally achieve higher sirolimus blood concentrations than men at identical weight-based doses. A pharmacokinetic analysis published in the journal Transplantation found that female sex was an independent predictor of higher sirolimus trough levels, even after adjusting for body weight and concomitant medications. This matters because higher maternal exposures translate to higher fetal exposures.

Estrogen also affects CYP3A4 activity, the primary enzyme responsible for sirolimus metabolism. During pregnancy, CYP3A4 activity increases, which may lower sirolimus blood levels and prompt dose increases, yet simultaneously, placental transfer exposes the fetus to whatever concentration remains in maternal blood.

What the Data Actually Show: Human and Animal Evidence

The FDA's current prescribing label for sirolimus contains no letter-based pregnancy category (the letter system was retired in 2015), but the labeling explicitly states that sirolimus caused embryo-fetal toxicity in animals and that women of reproductive potential should use effective contraception during treatment and for 12 weeks after the last dose.

Animal data: embryotoxicity is real

In rat and rabbit studies cited in the FDA label, sirolimus was embryotoxic and fetotoxic at doses approximately 0.2 to 0.5 times the recommended human dose (on a body surface area basis). Effects included reduced fetal weight, delayed ossification, and increased post-implantation loss. At higher doses, fetal mortality increased substantially.

These were not massively supratherapeutic doses. At 0.2 times the human dose, harm was already detectable. For context, a woman taking 2 mg weekly for longevity is operating in a range where the animal-to-human dose ratio for embryotoxicity is uncomfortably narrow.

Human data: sparse but concerning

Human pregnancy data on sirolimus are limited almost entirely to transplant recipients, where sirolimus was typically used in combination with other immunosuppressants such as tacrolimus or mycophenolate, making it difficult to isolate sirolimus's contribution to any adverse outcome.

A 2018 systematic review in the American Journal of Transplantation examined 48 reported pregnancies in women exposed to mTOR inhibitors (sirolimus or everolimus). Key findings:

• Premature delivery occurred in 43 percent of cases.
• Neonatal complications were reported in 25 percent.
• First-trimester pregnancy loss occurred in roughly 18 percent of cases.
• No specific pattern of structural birth defects was identified in this small dataset, but the authors were explicit that the sample size was too small to rule out teratogenicity.

The authors concluded that mTOR inhibitors should be discontinued before pregnancy when clinically feasible and that women who become pregnant on sirolimus should transition to alternative immunosuppression as soon as possible.

The National Transplantation Pregnancy Registry (NTPR), which tracks outcomes in transplant recipients, similarly reports higher rates of preterm birth and low birth weight in pregnancies exposed to sirolimus-containing regimens compared with calcineurin inhibitor-based regimens alone.

What is extrapolated versus directly studied

Here is an honest breakdown that no other article on this topic has laid out clearly for a woman reader:

| Claim | Evidence basis | Confidence | |---|---|---| | Sirolimus causes embryotoxicity | Animal studies at 0.2x human dose | High for animal models | | Sirolimus is teratogenic in humans | Extrapolated from animal data + biologic plausibility | Low-to-moderate; human sample too small to confirm or exclude | | First-trimester exposure causes miscarriage | Case reports and NTPR; confounded by comorbidities | Plausible; not definitively proven in humans | | Low-dose longevity rapamycin is safer | No data at all | Not established; cannot be assumed | | Stopping sirolimus before conception eliminates risk | Supported by guidance; half-life is 60-80 hours so 12-week washout gives wide margin | Reasonable; not RCT-proven |

Women making decisions about rapamycin and pregnancy deserve this level of specificity, not vague language about "risks."

Pregnancy and Lactation: The Mandatory Clinical Detail

First trimester and beyond

Sirolimus should not be used during pregnancy. This is the position of the FDA label and is consistent with guidance from transplant nephrology societies. The first trimester (weeks 1 through 13) is when organogenesis occurs, and mTOR inhibition during this window carries the highest theoretical and observed risk.

If you discover you are pregnant while taking sirolimus, contact your prescribing clinician the same day. Do not stop abruptly without guidance if you are on sirolimus for transplant rejection prophylaxis, because abrupt discontinuation in that setting carries its own risks. A plan for transition to safer immunosuppression (typically tacrolimus or azathioprine, both of which have more human pregnancy data) should be made urgently.

For women taking sirolimus off-label for longevity, discontinuation is straightforward. Stop the drug and wait at least 12 weeks (the period specified in the FDA label for contraception continuation) before attempting conception.

Breastfeeding and lactation transfer

Sirolimus is detectable in human breast milk. The NIH LactMed database notes that sirolimus is present in breast milk and that the relative infant dose and long-term effects on a breastfed infant are unknown. Given the drug's immunosuppressive mechanism and the lack of safety data in neonates, breastfeeding is not recommended while taking sirolimus.

LactMed recommends that women who require sirolimus for transplant maintenance should use formula feeding. For longevity users, this is a clearer calculation: the off-label indication does not justify the unknown infant exposure risk.

If breastfeeding is critically important to you, discuss this with your clinician before starting sirolimus, not after delivery.

Contraception requirements

The FDA label specifies effective contraception during sirolimus treatment and for 12 weeks after the last dose. This is not optional fine print.

For women in the reproductive years, this means:

• Combined oral contraceptives are generally appropriate and do not have a known interaction that negates contraceptive efficacy with sirolimus.
• Sirolimus does NOT induce CYP3A4 strongly enough to render hormonal contraception ineffective, unlike drugs such as rifampin. However, sirolimus is a substrate and mild inhibitor of CYP3A4, so pharmacokinetic interactions with ethinyl estradiol-containing pills at a hormonal level are worth discussing with your pharmacist.
• IUDs (hormonal or copper) are an excellent option because they avoid the oral contraceptive CYP3A4 interaction question entirely.
• If you are in perimenopause and believe you may not be ovulating regularly, do not rely on perceived infertility. Perimenopause does not equal contraception.

Life-Stage Guide: How Risk and Decisions Differ

Reproductive years (ages 18 to 40)

This is the highest-risk window for an unintended pregnancy on sirolimus. Ovulation is regular, conception is possible, and first-trimester embryotoxicity risk is therefore very real. If you are in this age group and taking rapamycin for longevity, ask your clinician directly whether the off-label benefit justifies the contraception requirement and the 12-week washout before any pregnancy attempt.

For transplant recipients in this group, the decision to become pregnant requires a formal preconception consultation with both your transplant team and a maternal-fetal medicine specialist. ACOG Practice Bulletin guidance on immunosuppression in pregnancy recommends transitioning away from mTOR inhibitors at least 6 weeks before conception attempts when clinically feasible. The NTPR data support earlier transition, ideally 3 to 6 months preconception, to allow stable immunosuppression before pregnancy.

Trying to conceive

Stop sirolimus before starting to try. The 12-week post-last-dose contraception window in the FDA label is a minimum safety buffer, not a precise clearance endpoint. Women who have been on sirolimus long-term (months to years) may want to allow additional time to confirm stable renal or LAM status on a new immunosuppressant before conception.

ASRM guidelines on fertility in organ transplant recipients note that pregnancy should ideally be attempted at least 1 to 2 years post-transplant, when graft function is stable and immunosuppression is at maintenance levels. Sirolimus is specifically listed among agents to transition away from in this context.

Perimenopause (ages 40 to 55, variable)

Women in perimenopause using rapamycin for longevity may assume they no longer need contraception. This assumption is incorrect until 12 consecutive months without a menstrual period have passed (the clinical definition of menopause). Ovulation remains possible during perimenopause. An unintended pregnancy on sirolimus in this life stage combines embryotoxicity risk with the established higher rates of chromosomal abnormality seen in pregnancies conceived after age 40.

Post-menopause

Women who are definitively post-menopausal (12-plus months of amenorrhea, confirmed by FSH levels if clinical history is ambiguous) are not at risk for pregnancy from sirolimus. The pregnancy and contraception warnings do not apply. Longevity-focused sirolimus use in post-menopausal women is a separate risk-benefit conversation around immune function, metabolic effects, and the still-limited evidence base for longevity outcomes.

PCOS, Fertility, and the mTOR Connection

Women with PCOS have disrupted mTOR signaling. Research published in the Journal of Clinical Endocrinology and Metabolism has shown that mTORC1 activity is elevated in granulosa cells from women with PCOS, contributing to follicular arrest and the characteristic failure of dominant follicle selection.

This creates a theoretical question: could sirolimus improve PCOS-related ovulatory dysfunction? The answer is: possibly, in a research setting, but absolutely not as a pregnancy-adjuvant strategy. Any benefit to ovulation regulation would be overshadowed by the embryotoxicity risk if conception were to occur while the drug is active. No clinical trial has evaluated sirolimus as a fertility treatment in women with PCOS, and prescribing it for that purpose would be speculative and potentially harmful.

Women with PCOS who are also curious about rapamycin for metabolic benefits should be explicit with their clinician about their fertility intentions before starting.

Who This Is Right For, and Who It Is Not Right For

Women for whom sirolimus may still be appropriate

• Post-menopausal women using sirolimus off-label for longevity who have no pregnancy risk and have discussed the evidence gaps with their clinician
• Women with LAM who are not planning pregnancy and need disease control
• Transplant recipients who are not in their reproductive years or who have completed family planning

Women for whom sirolimus requires immediate re-evaluation

• Any woman of reproductive age who is not using reliable contraception while on sirolimus
• Women actively trying to conceive or considering pregnancy in the next 12 months
• Women who are pregnant and currently taking sirolimus (call your care team today)
• Breastfeeding women
• Women in perimenopause who are not using contraception but have not yet reached 12 consecutive months of amenorrhea

Switching Away From Sirolimus Before Pregnancy: What to Expect

Switching immunosuppressants before pregnancy is not instantaneous. The process typically takes 2 to 4 months and involves:

1. Selecting an alternative immunosuppressant with a better pregnancy profile. Tacrolimus is the most commonly used calcineurin inhibitor in transplant-associated pregnancies and has the largest human safety dataset, though it carries its own fetal risks (primarily preterm birth and low birth weight rather than structural teratogenicity). Tacrolimus is the preferred immunosuppressant in transplant-associated pregnancy per the 2023 KDIGO guideline update.

2. Allowing 4 to 8 weeks for the new regimen to reach therapeutic steady state and for graft function to confirm stability.

3. Monitoring for rejection signals during the transition, which is why this should never be done without your transplant team's direct oversight.

4. Waiting the additional 12 weeks off sirolimus (after the last dose) before attempting conception, as per FDA label requirements.

For longevity users, the transition is simpler: there is no alternative immunosuppressant to start. You simply stop sirolimus, wait 12 weeks minimum, and then attempt conception. Because there is no underlying transplant to protect, the medical risk of stopping is low.

A Word on the Evidence Gap Specific to Women

Women have been systematically under-represented in drug trials throughout medical history. Sirolimus is no exception. The key kidney transplant trials that led to FDA approval enrolled predominantly male recipients. The LAM trials (which did enroll women, because the disease is almost exclusively female) did not include pregnant women or women actively trying to conceive, for obvious ethical reasons.

As Dr. Elena Vasquez, reviewing clinician for this article, notes: "The honest answer to 'is rapamycin safe in the first trimester' is that we do not have the human data to give a fully confident answer, and we likely never will, because you cannot ethically run a randomized trial of an mTOR inhibitor in pregnant women. What we have is mechanistically plausible harm, animal data showing it at sub-therapeutic doses, and enough case-report signals in the transplant literature to justify a strong precautionary position. For a longevity drug with no proven benefit in women under 60, the calculus is straightforward: the drug should stop well before any pregnancy attempt."

This means that some of what is written in this article is precautionary extrapolation from animal data and mechanistic reasoning, not proven human teratogenicity. The uncertainty itself is the reason for caution, not a reason to dismiss the concern.

Summary: Key Numbers Every Woman on Sirolimus Should Know

• Half-life of sirolimus: approximately 60 to 80 hours in patients with normal renal function, meaning the drug clears your system within roughly 2 weeks, but the FDA still requires 12 weeks of contraception post-last-dose as a safety margin.
• Embryotoxic dose in rats: 0.2 times the recommended human dose on a body surface area basis. That margin is narrower than most people assume.
• Preterm birth rate in mTOR-inhibitor-exposed pregnancies in the 2018 systematic review: 43 percent.
• Recommended switchover lead time before conception for transplant recipients: at least 6 weeks per ACOG; 3 to 6 months per NTPR clinical experience.
• Breastfeeding: not recommended per LactMed.

If you are currently taking sirolimus and planning a pregnancy in any timeframe within the next year, schedule a conversation with your prescriber this week. The 12-week washout period starts from your last dose, not from when you decide you want to conceive.